← Eichor
Condition: Advanced Er Her2 Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Er Her2 Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07014410Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patien
Phase 1/Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07235176Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/
Phase 1/Phase 2 · 14 location(s) · Ellipses Pharma · NCT05573126A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
Phase N/A · 3 location(s) · iOMEDICO AG · NCT07563595Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 · 203 location(s) · Celcuity Inc · NCT06757634A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Phase 3 · 2 location(s) · InventisBio Co., Ltd · NCT06954961A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662Elacestrant in Advanced Triple Positive Breast Cancer
Phase 1/Phase 2 · 1 location(s) · NYU Langone Health · NCT07612215PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Phase 1 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT04360941A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Phase 2 · 3 location(s) · Reshma L. Mahtani, D.O. · NCT06263543A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · 233 location(s) · Olema Pharmaceuticals, Inc. · NCT06016738Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3 · 99 location(s) · MedSIR · NCT06382948PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2 · 1 location(s) · Kristina A. Fanucci · NCT07222215A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com
Phase 1/Phase 2 · 14 location(s) · AstraZeneca · NCT06188520Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06500208A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
Phase 2 · 2 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06000917A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Particip
Phase 3 · 352 location(s) · Hoffmann-La Roche · NCT06065748A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recu
Phase 2/Phase 3 · 295 location(s) · Bristol-Myers Squibb · NCT06926868A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrin
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06656624A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Phase 1 · 13 location(s) · Pfizer · NCT07318805Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · 167 location(s) · Olema Pharmaceuticals, Inc. · NCT07085767A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Phase 1 · 1 location(s) · Kind Pharmaceuticals LLC · NCT05187832A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Phase 1/Phase 2 · 1 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT07002177Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+,
Phase 1 · 16 location(s) · Olema Pharmaceuticals, Inc. · NCT05508906
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.